Technology Insight: Novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs

Nature Clinical Practice Oncology

Volumn 5, Issue 1, 2008, Pages 44-54

  Weber, Wolfgang A ^a   Czernin, Johannes ^b   Phelps, Michael E ^b   Herschman, Harvey R ^b  

^a TU BERGAKADEMIE FREIBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBON 11; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUOROURACIL; GALLIUM 68; GEFITINIB; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NANOPARTICLE; PACLITAXEL; RAPAMYCIN; TANESPIMYCIN; TEMOZOLOMIDE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; VITRONECTIN RECEPTOR; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR PROTEIN;

BIOLUMINESCENCE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; TUMOR BIOPSY; ANIMAL; BINDING COMPETITION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; PATIENT SELECTION; SCINTISCANNING; SIGNAL TRANSDUCTION; STATISTICS; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NEOPLASM PROTEINS; NEOPLASMS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 38449107451     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0982     Document Type: Review

References (54)

1. Sawyers C (2004) Targeted cancer therapy. Nature 432: 294-297
2. Vogel CL et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
3. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
4. Atkins MB et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909-918
5. Collins I and Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2: 689-700
6. Workman P et al. (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98: 580-598
7. Perik PJ et al. (2006) Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24: 2276-2282
8. Ntziachristos V et al. (2005) Looking and listening to light: The evolution of whole-body photonic imaging. Nat Biotechnol 23: 313-320
9. Cherry SR (2006) The 2006 Henry N. Wagner Lecture: Of mice and men (and positrons) - advances in PET imaging technology. J Nucl Med 47 1735-1745
10. Blodgett TM et al. (2007) PET/CT: Form and function. Radiology 242: 360-385
11. Linden HM et al. (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24: 2793-2799
12. Beer AJ et al. (2005) Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46: 1333-1341
13. Mintun MA et al. (1988) Breast cancer: PET imaging of estrogen receptors. Radiology 169: 45-48
14. Larson SM et al. (2004) Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45: 366-373
15. Hofmann M et al. (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 28: 1751-1757
16. Schottelius M et al. (2004) First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 10: 3593-3606
17. Haubner R et al. (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med 2: 244-252
18. Wu AM and Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146
19. Backer MV et al. (2007) Molecular imaging of VEGF receptors in angiogenic vasculature-with single-chain VEGF-based probes. Nat Med 13:504-509
20. Sharma P et al. (2006) Nanoparticles for bioimaging. Adv Colloid Interface Sci 123-126: 471-485
21. Gao X et al. (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22: 969-976
22. Ntziachristos V et al. (2002) Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 8: 757-760
23. Hutchinson OC et al. (2003) Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des 9: 917-929
24. Jayson GC et al. (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94: 1484-1493
25. Shani J, and Wolf W (1977) A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 37: 2306-2308
26. Hsueh WA et al. (2006) Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J Nucl Med 47: 1995-1999
27. Saleern A et al. (2003) Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63: 2409-2415
28. Saleern A et al. (2001) Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 19: 1421-1429
29. Bergstrom M et al. (2003) Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59: 357-366
30. Bading JR et al. (2003) Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: A positron emission tomography study in rats. Cancer Res 63: 3667-3674
31. Nunn AD (2006) The cost of developing imaging agents for routine clinical use. Invest Radiol 41: 206-212
32. Lee CC et al. (2005) Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science 310: 1793-1796
33. Dehdashti F et al. (1999) Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26: 51-56
34. Haubner R et al. (2001) Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61: 1781-1785
35. Bremer C et al. (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7: 743-748
36. Pal A et al. (2006) Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8: 262-277
37. Smith-Jones PM et al. (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22 701-706
38. Smith-Jones PM et al. (2006) Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J Nucl Med 47 793-796
39. O'Connor JP et al. (2007) DCE-MRI biomarkers in the clinical evaluation of antianglogenic and vascular disrupting agents. Br J Cancer 96: 189-195
40. Thomas AL et al. (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 4162-4171
41. Morgan B et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21: 3955-3964
42. Paez JG et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
43. Leach MO et al. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 92 1599-1610
44. Massoud TF et al. (2007) Reporter gene imaging of protein-protein interactions in living subjects. Curr Opin Biotechnol 18: 31-37
45. Paulmurugan R et al. (2002) Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci USA 99: 15608-15613
46. Luker KE et al. (2004) Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci USA 101: 12288-12293
47. Weber WA (2006) Positron emission tomography as an imaging biomarker. J Clin Oncol 24: 3282-3292
48. Shankar LK et al. (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47: 1059-1066
49. Juweid ME et al. (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25: 571-578
50. Van den Abbeele AD and Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 (suppl 5): S60-S65
51. Su H et al. (2006) Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12: 5659-5667
52. Vesselle H et al. (2002) In vivo validation of 3′deoxy- 3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8: 3315-3323
53. Chen W et al. (2005) Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 46: 945-952
54. Chen W et al. (2006) Predicting response of malignant brain tumors to bevacizumab and irinotecan therapy with FLT and FDOPA PET [abstract #78P]. J Nucl Med 47